Clinical Case Series on Assessment of Therapeutic Efficacy of Saroglitazar in MASLD Patients

Objective: This prospective case series aimed to evaluate the efficacy of saroglitazar 4 mg in improving clinical parameters in patients with type 2 diabetes mellitus (T2DM) with steatotic liver disease (SLD), focusing on glycemic control, lipid profile, liver enzymes, and transient elastography parameters (CAP and LSM scores).

Materials and Methods: Eight T2DM patients having SLD; defined as Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) were enrolled from a single-center, Dr. Dang’s Clinic, Ghaziabad, Uttar Pradesh India. Saroglitazar 4 mg was administered daily, and various clinical parameters were monitored at baseline, 16 weeks, and 32 weeks. Statistical analysis was performed using paired t-tests to assess changes over time.

Results: Saroglitazar treatment significantly reduced HbA1c, Triglycerides (TG), Alanine aminotransferase (ALT), transient elastography parameters (CAP and LSM) along with other lipid and glycemic parameters from baseline to weeks 32. These findings underscore potential role of saroglitazar in managing T2DM and associated SLD by improving metabolic parameters and liver health.

Conclusion: Saroglitazar showed significant improvements in glycemic control, lipid profile, liver enzymes, liver fat and fibrosis in MASLD patients, indicating its potential as a therapeutic option for managing metabolic abnormalities and liver complications. Further research is needed to validate these findings.